Boston Family Office LLC Sells 858 Shares of Stryker Co. (NYSE:SYK)

Boston Family Office LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,401 shares of the medical technology company's stock after selling 858 shares during the period. Stryker accounts for about 1.5% of Boston Family Office LLC's portfolio, making the stock its 21st biggest position. Boston Family Office LLC's holdings in Stryker were worth $22,467,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares during the period. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker in the fourth quarter worth $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker in the fourth quarter worth $33,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SYK shares. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Stifel Nicolaus raised their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Finally, Citigroup reiterated a "buy" rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $421.90.

Stryker Stock Performance

NYSE:SYK traded down $22.01 during trading on Friday, reaching $346.14. The company's stock had a trading volume of 3,956,734 shares, compared to its average volume of 1,321,179. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market cap of $132.12 billion, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The firm has a 50 day moving average of $381.69 and a 200-day moving average of $374.30. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. Stryker's payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.